These data include high-dimensional omics (e.g. genomic and proteomic) data, as well as data collected via electronic health records, multiple clinical trials targeting similar outcomes (e.g. progression to later-stage type 1 diabetes), surveys, fitness wearables, mobile apps, glucose monitors and insulin delivery devices [20]. This evidence concerns the gene INS and type 1 diabetes mellitus.